VVOSNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. develops and commercializes oral appliance-based therapies and related clinical protocols for obstructive sleep apnea and other sleep-disordered breathing conditions. The company works through trained dental and medical providers and also operates sleep and airway medicine centers that support diagnosis, treatment, and patient management in the United States.

Kysy yhtiöstä
Liikevaihto17,4milj. USD
+16,0 %v/v
Liikevoitto (EBIT)−19,9milj. USD
−78,1 %v/v
EBIT-marginaali−114,1%
−39,7 %-yks.v/v
Nettotulos−21,2milj. USD
−90,1 %v/v
Vapaa kassavirta−17,6milj. USD
−32,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−30−20−1001020milj. USD2020: 13 milj. USD2020: EBIT −12 milj. USD20202021: 17 milj. USD2021: EBIT −20 milj. USD20212022: 16 milj. USD2022: EBIT −25 milj. USD20222023: 14 milj. USD2023: EBIT −17 milj. USD20232024: 15 milj. USD2024: EBIT −11 milj. USD20242025: 17 milj. USD2025: EBIT −20 milj. USD202517−20
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Vivos Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Oral appliance systems45 %

Custom oral devices used in sleep apnea and airway treatment protocols.

Clinical services and enrollments20 %

VIP enrollments, training, and support services for provider networks.

Sleep center operations25 %

Diagnostic, consulting, and treatment services delivered through managed centers.

Adjunctive therapies and support10 %

Additional therapies, technical support, and patient-care services tied to the platform.

Tuotteet

Raportoitu · osuus liikevaihdosta
34,6%18,8%18,4%12,5%8,6%FY2025100 %
  • Sleep Testing Services34,6 %
  • Appliances18,8 %
  • Tooth Positioners18,4 %
  • Treatment Centers12,5 %
  • Sponsorship Seminar Other7,0 %
  • Muut8,6 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company sells to dental practices, sleep medicine providers, and medical professionals who use its appliances and protocols to treat obstructive sleep apnea and related airway conditions. It also serves patients through managed sleep and airway medicine centers, where diagnostics and treatment pathways can be coordinated with provider networks.

VIP dental practices

Independent dentists that enroll to prescribe and support Vivos oral appliance therapy and related services.

Sleep and airway medicine centers

Managed centers that provide diagnostics, consulting, and treatment pathways for sleep-disordered breathing.

Medical sleep providers

Physicians and advanced practice clinicians who participate in center-based sleep care and referrals.

Patients with OSA and snoring

End users receiving appliance-based therapy, diagnostics, and adjunctive treatment services.

Strategia

The company is shifting from a provider-enrollment model toward owning or partnering with sleep and airway medicine centers that can generate diagnostics, consulting, and appliance revenue together. It is also pursuing acquisitions and strategic alliances to expand patient flow, broaden distribution, and build a more integrated care platform around its oral appliance therapies.

Build a center-based sleep medicine modelLyhyt aikaväli

Owning or managing centers can create more direct patient access and additional revenue streams.

Expand strategic alliances and acquisitionsKeskipitkä aikaväli

Partnerships can increase patient volume and broaden distribution without relying only on VIP recruitment.

Strengthen clinical validationKeskipitkä aikaväli

Clinical evidence supports provider adoption, payer acceptance, and regulatory credibility.

Maantiede

Vivos is primarily a United States business, with product commercialization, provider training, and sleep-center operations centered in the U.S. The company has also referenced international treatment experience and distribution collaborations, including a Middle East-North Africa channel, but those initiatives are not yet a major revenue base.

Riskit

Vivos faces execution risk as it transitions to a new operating model that depends on acquisitions, alliances, and center integration rather than the legacy VIP channel. The business also carries financing, Nasdaq compliance, reimbursement, regulatory, and trade-sourcing risks that can affect its ability to operate, scale, and convert clinical demand into revenue.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Liquidity and financing risk1Transition to a new sales and distribution model may fail2Acquisition and integration risk3Regulatory and fee-splitting risk4Reimbursement and payer policy risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Liquidity and financing riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company has indicated it needs additional capital to fund operations and strategic objectives.

    KohdistuuDebt/equity financingGoing concern
  2. Transition to a new sales and distribution model may failVaikutus: KorkeaTodennäköisyys: Korkea

    The company is moving away from VIP recruitment toward center-based care, which has limited operating history.

    KohdistuuRevenue growthCustomer acquisitionOperating model
  3. Acquisition and integration riskVaikutus: KorkeaTodennäköisyys: Korkea

    Integrating sleep centers can be costly and operationally disruptive, affecting patients, staff, and standards.

    Kohdistuu: Sleep Center of Nevada and future acquisitions

  4. Regulatory and fee-splitting riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Managed medical arrangements must comply with state corporate practice and fee-splitting laws.

    Kohdistuu: Center operations and physician arrangements

  5. Nasdaq listing and equity requirement complianceVaikutus: Korkea

    Failure to maintain compliance could impair stock liquidity and capital raising ability.

    Kohdistuu: Public market access

  6. Reimbursement and payer policy riskVaikutus: KeskitasoTodennäköisyys: Korkea

    Coverage decisions and reimbursement rates affect the economics of sleep testing and treatment.

    Kohdistuu: Diagnostics and treatment services

Kysy Clarifolta: Vivos Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition under ASC 606

Appliance sales, enrollments, and service contracts may recognize revenue at different times.

Vaikutus: Affects quarterly revenue mix and comparability

Contract liabilities

Deferred service revenue is recognized as performance obligations are satisfied.

Vaikutus: Can shift revenue between periods

Capitalized software development

Internal-use software spending is capitalized and later amortized.

Vaikutus: Affects operating expense timing and asset balances

Acquisition and intangible asset accounting

Center acquisitions may create goodwill and identifiable intangibles requiring future impairment testing.

Vaikutus: Could materially affect balance sheet and earnings

Going-concern and equity deficit disclosures

Liquidity assumptions and financing plans influence financial statement presentation and investor assessment.

Vaikutus: Important for solvency and valuation analysis

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Vivos Inc

RDGL · Surgical & Medical Instruments & Apparatus

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

Viemed Healthcare, Inc

VMD · Services-Misc Health & Allied Services, NEC

Avanos Medical, Inc

Orthopedic, Prosthetic & Surgical Appliances & Supplies

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

Inspire Medical Systems, Inc.

INSP · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Vivos Therapeutics, Inc. (VVOS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo